Item 5.08Shareholder Director Nominations

Armata Pharmaceuticals, Inc. ("Armata" or the "Company") has set June 12, 2024 as the date for its 2024 annual meeting of stockholders (the "Annual Meeting"). The Annual Meeting will be held at 8:30 a.m. (Pacific Time), via virtual web service, to be announced publicly prior to the Annual Meeting, or at such other time and location to be determined by the Company's Board of Directors and set forth in the Company's proxy statement for the Annual Meeting. Armata's stockholders of record at the close of business on April 19, 2024, will be entitled to notice of the Annual Meeting and to vote upon matters considered at the Annual Meeting.

Because the date of the Annual Meeting represents a change of more than 30 days from the anniversary of Armata's 2023 annual meeting of stockholders, Armata has set new deadlines for (i) the receipt of stockholder proposals submitted pursuant to Rule 14a-8 of the Securities Exchange Act of 1934, as amended ("Exchange Act"), for inclusion in Armata's proxy materials for the Annual Meeting ("Rule 14a-8 Deadline") and (ii) receipt of stockholder proposals and director nominations submitted pursuant to Article II, Section 2.6 of Armata's Amended and Restated Bylaws for consideration at the Annual Meeting ("Advance Notice Bylaws Provision Deadline"). The Rule 14a-8 Deadline is 5:00 p.m. (Eastern Time) on Monday, April 1, 2024, which Armata has determined to be a reasonable period of time before it expects to begin to print and send its proxy materials. The Advance Notice Bylaws Provision Deadline is 5:00 p.m. (Eastern Time) on Monday, April 1, 2024. Stockholder proposals and director nominations should be submitted in writing and must be received by the Corporate Secretary at Armata's principal executive offices at Armata Pharmaceuticals, Inc., 5005 McConnell Avenue, Los Angeles, California 90066, by the Rule 14a-8 Deadline or the Advance Notice Bylaws Provision Deadline, as applicable, in order to be considered timely.

Stockholder proposals submitted in accordance with Rule 14a-8 of the Exchange Act must also comply with the remaining requirements of Rule 14a-8 of the Exchange Act in order to be considered for inclusion in the proxy materials for the Annual Meeting.

Stockholder proposals and nominations submitted pursuant to Armata's advance notice bylaw provisions must also comply with the advance notice provisions contained in Armata's Amended and Restated Bylaws and may be omitted if not in compliance with applicable requirements. Stockholders are urged to read the complete text of such advance notice provisions.

Attachments

  • Original Link
  • Permalink

Disclaimer

Armata Pharmaceuticals Inc. published this content on 22 March 2024 and is solely responsible for the information contained therein. Distributed by Public, unedited and unaltered, on 22 March 2024 12:03:05 UTC.